Company intelligence / Profile preview

Hunan Zhaotai Medical Group

Ownership: Private
Employees: ~130
Development stage: Phase 1

Overview

The company has developed a novel CAR T-cell construct with a unique, patented co-stimulatory domain that produces stronger anti-cancer activity in the laboratory than existing second-generation CAR T-cells. Preliminary clinical data suggests an improved safety profile with fewer side effects than competing CAR T-cell treatments. Phase I trials have been conducted for various cancers, and results of the ENABLE trial in New Zealand were due to be published in 2023.

Therapeutic areas: Oncology
Modalities: CAR T-cell therapiesTIL therapyNatural Killer Cell Therapies
Industry: Biotech

Partnerships

Wellington Zhaotai Therapies (joint venture with Malaghan Institute of Medical Research)Dr. Reddy's Laboratories

Beyond the preview

Go deeper on Hunan Zhaotai Medical Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hunan Zhaotai Medical Group.

Explore the full profile